Maeda K - Search Results

1

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.

Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: maeda k. N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9. N Engl J Med. 2022. PMID: 35263535 Free PMC article. No abstract available.

2

The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection.

Maeda K, Nakata H, Ogata H, Koh Y, Miyakawa T, Mitsuya H. Maeda K, et al. Curr Opin Pharmacol. 2004 Oct;4(5):447-52. doi: 10.1016/j.coph.2004.07.004. Curr Opin Pharmacol. 2004. PMID: 15351348 Review.

3

Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.

Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H. Nakata H, et al. Among authors: maeda k. J Virol. 2005 Feb;79(4):2087-96. doi: 10.1128/JVI.79.4.2087-2096.2005. J Virol. 2005. PMID: 15681411 Free PMC article.

4

Development of therapeutics for AIDS: structure-based molecular targeting.

Maeda K, Mitsuya H. Maeda K, et al. Tuberculosis (Edinb). 2007 Aug;87 Suppl 1:S31-4. doi: 10.1016/j.tube.2007.05.009. Epub 2007 Jul 10. Tuberculosis (Edinb). 2007. PMID: 17625972 Review.

5

Development of protease inhibitors and the fight with drug-resistant HIV-1 variants.

Mitsuya H, Maeda K, Das D, Ghosh AK. Mitsuya H, et al. Among authors: maeda k. Adv Pharmacol. 2008;56:169-97. doi: 10.1016/S1054-3589(07)56006-0. Adv Pharmacol. 2008. PMID: 18086412 Review. No abstract available.

6

[Structure-guided molecular-targeting approach for development of AIDS therapeutics].

Maeda K, Mitsuya H. Maeda K, et al. Nihon Rinsho. 2010 Oct;68(10):1889-95. Nihon Rinsho. 2010. PMID: 20954335 Review. Japanese.

7

CCR5 inhibitors: emergence, success, and challenges.

Maeda K, Das D, Nakata H, Mitsuya H. Maeda K, et al. Expert Opin Emerg Drugs. 2012 Jun;17(2):135-45. doi: 10.1517/14728214.2012.673584. Epub 2012 Apr 25. Expert Opin Emerg Drugs. 2012. PMID: 22533737 Review.

8

EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium.

Matsuzawa T, Kawamura T, Ogawa Y, Maeda K, Nakata H, Moriishi K, Koyanagi Y, Gatanaga H, Shimada S, Mitsuya H. Matsuzawa T, et al. Among authors: maeda k. J Invest Dermatol. 2014 Apr;134(4):1158-1161. doi: 10.1038/jid.2013.467. Epub 2013 Nov 11. J Invest Dermatol. 2014. PMID: 24384694 Free PMC article. No abstract available.

9

Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.

Das D, Maeda K, Hayashi Y, Gavande N, Desai DV, Chang SB, Ghosh AK, Mitsuya H. Das D, et al. Among authors: maeda k. Antimicrob Agents Chemother. 2015 Apr;59(4):1895-904. doi: 10.1128/AAC.04654-14. Epub 2015 Jan 12. Antimicrob Agents Chemother. 2015. PMID: 25583709 Free PMC article.

10

HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.

Yasutake Y, Hattori SI, Hayashi H, Matsuda K, Tamura N, Kohgo S, Maeda K, Mitsuya H. Yasutake Y, et al. Among authors: maeda k. Sci Rep. 2018 Jan 26;8(1):1624. doi: 10.1038/s41598-018-19602-9. Sci Rep. 2018. PMID: 29374261 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,808 results

Search Page